✓ No active regulatory warningsFDA MedWatch, EMA EudraVigilance, WHO VigiBase, WADA Prohibited List · 2026-05-29
📰Read the full Berberine evidence review on GMJ News →Complete clinical article, references and updates on news.gmj.ge. This page is the structured safety summary.⚠ Pregnant woman taking berberine — CONTRAINDICATED (uterotonic, crosses placenta, bilirubin displacement) [1]
⚠ Patient on cyclosporine + berberine — CYP3A4 inhibition increases cyclosporine levels by ~35% [2]
⚠ Patient combining berberine + metformin without physician guidance — additive AMPK activation + additive GI effects + hypoglycemia risk [2]
⚠ Patient on statins + berberine — CYP3A4 inhibition increases statin levels (myopathy risk) [2]
⚠ Neonate exposed to berberine (via maternal use or direct) — bilirubin displacement, kernicterus risk [1]
ℹ️ Not obtained from food. Not applicable — this is not obtained from food in meaningful amounts; supplementation is the practical route.
🔬 Lab interpreter
Recommended test
Fasting blood glucose and HbA1c
Fasting blood glucose and HbA1c
Reference range / target
Per diabetes guidelines
Per diabetes guidelines
Primary monitoring for glucose-lowering efficacy. Expected: FBG −0.9 mmol/L, HbA1c −0.7% [3].
Full lab monitoring ↓⚕ For professionals — confirm ranges against your local laboratory.
Clinical verdict
Berberine is the best-evidenced 'natural' glucose-lowering agent — meta-analysis shows HbA1c −0.7% and fasting glucose −0.9 mmol/L. It activates AMPK like metformin but lacks outcome trial data. CRITICAL: inhibits CYP3A4/CYP2D6 (major drug interactions), causes GI upset in 10–30%, and is CONTRAINDICATED in pregnancy (uterotonic + bilirubin displacement). NOT a metformin replacement — an option for prediabetes or metformin-intolerant patients [2] [3].
1 How much do I need?
👤 Adults: Specific dosage data under clinical review
👴 Elderly: Specific dosage data under clinical review
🤰 Pregnancy: See guidance
CONTRAINDICATED. Uterotonic activity, crosses placenta, bilirubin displacement (kernicterus risk in neonates). Do not use during pregnancy or lactation [1].
👦 Pediatric: See guidance
NOT recommended in children. Berberine displaces bilirubin from albumin binding sites — this is particularly dangerous in neonates (risk of kernicterus) [1]. No pediatric safety data exists for supp
🏃 Athletes: Standard dose
⚖️ Obesity: Standard dose
Fat-soluble compounds may require dose adjustment in obesity.
🩺 Renal: Consult specialist
Dose adjustment may be needed in renal impairment.
🌱 Vegan: Standard dose
How to take
🍽 Timing: Take with meals (reduces GI side effects and may improve absorption). Divide dose: 500 mg TID, not 1,500 mg once daily [3].
💊 With food: Always with food. Fiber-rich meals may slightly reduce absorption [2].
2 Which form?
| Form | Bioavailability | Vegan | Cost |
|---|---|---|---|
| ['Berberine HCl', 'common', 'Standard supplemental form. Most clinical trials use this. Typical dose: 500 mg TID with meals [3].'] | Standard | Check label | |
| ['Berberine phytosome', '', 'Phospholipid complex for improved absorption. Emerging formulation with potentially lower dose requirements [2].'] | Standard | Check label | |
| ['Dihydroberberine (DHB)', 'preferred', 'Reduced form with ~5× greater intestinal absorption than berberine HCl. Converted back to berberine in the gut wall. Lower dose needed (200–300 mg) [2].'] | Standard | Check label |
3 Common questions
Is berberine as good as metformin? ▼
One small Chinese RCT showed comparable glucose and HbA1c reduction, and a meta-analysis of 27 trials confirmed significant metabolic effects [3] [4]. However: metformin has decades of outcome data (UKPDS), established safety in long-term use, FDA approval, and proven cardiovascular benefit. Berberine has surrogate marker data only, limited long-term safety data, and significant CYP interactions. It is NOT a proven metformin replacement — it is an option for patients who cannot tolerate metformin or prefer a natural approach to prediabetes.
Why does berberine cause diarrhea? ▼
Berberine has direct antimicrobial effects in the gut, alters the microbiome, and is poorly absorbed — most of the oral dose remains in the GI tract [2]. Diarrhea, cramping, and bloating are dose-related and affect 10–30% of users. Starting low (500 mg/day) and titrating up over 1–2 weeks, always with meals, minimizes GI effects [3].
Can I combine berberine with my diabetes medications? ▼
Use extreme caution. Berberine activates AMPK (like metformin) and lowers glucose — adding it to metformin, sulfonylureas, or insulin creates hypoglycemia risk [2] [3]. Additionally, berberine inhibits CYP3A4, which metabolizes many drugs. ALWAYS discuss with your physician before combining berberine with any diabetes medication.
How long until berberine works? ▼
Metabolic effects (glucose, lipids) typically become apparent within 4–12 weeks of consistent dosing at 1,500 mg/day [3]. It is not a fast-acting supplement — compliance and patience are required.
4 Clinical evidence
Strong
AMPK activation: berberine activates AMPK comparably to metformin in cellular and animal studies [2]. Glucose reduction: meta-analysis of 27 RCTs (n = 2,569) showed fasting glucose reduction of −0.9 mmol/L and HbA1c reduction of −0.7% [3]. Lipid reduction: same meta-analysis showed LDL reduction of −0.6 mmol/L and TG reduction of −0.4 mmol/L [3]. Antimicrobial: effective against various GI pathogens including bacterial diarrhea (long-standing traditional use confirmed in clinical trials) [1]. HIGH
Moderate
NAFLD: berberine 500 mg TID reduced hepatic fat content in a small RCT [4]. Polycystic ovary syndrome: improved insulin resistance and metabolic parameters in several small RCTs [2]. Gut microbiome modulation: berberine alters gut microbiota composition, which may contribute to its metabolic effects [2]. Weight loss: modest effect (~2–3 kg over 12 weeks in metabolic syndrome) [3]. MODERATE
Insufficient
Cardiovascular event reduction: no outcome trials (only surrogate marker data) [3]. Cancer treatment/prevention: preclinical data only [1]. Alzheimer disease: preclinical AMPK/neuroprotection data [2]. Long-term safety (>1 year of continuous use): limited data [2]. Direct comparison with metformin in head-to-head RCTs: one small Chinese trial showed comparable efficacy, but replication in diverse populations is needed [4]. LOW
5 Safety, toxicity & adverse events
Absolute contraindications
✕ Neonates — berberine displaces bilirubin from albumin, causing kernicterus risk
✕ Pregnancy — uterotonic; animal studies show teratogenicity
Relative
⚠ Concurrent metformin — additive hypoglycemia and GI effects (diarrhea)
⚠ Concurrent CYP3A4/CYP2D6 substrates — berberine inhibits these enzymes (increases cyclosporine, statins)
⚠ Concurrent macrolide antibiotics — additive QT prolongation
⚠ Hypotension — berberine lowers blood pressure
🚩 Red flags
● Pregnant woman taking berberine — STOP immediately. Contraindicated [1]
● Patient on cyclosporine, tacrolimus, or narrow TI drugs starting berberine — CYP3A4 inhibition; consult physician [2]
● Patient on metformin + berberine experiencing hypoglycemia — reduce berberine or adjust metformin [3]
● Newborn exposed to berberine — bilirubin displacement risk, monitor for jaundice [1]
6 Interactions
Drug interactions
Metformin Major
Mechanism: Both activate AMPK. Additive glucose-lowering. Additive GI side effects (diarrhea). [2]
Action: Physician supervision required. Monitor glucose closely. May need to reduce metformin dose [2].
Cyclosporine Major
Mechanism: Berberine inhibits CYP3A4 and P-glycoprotein, increasing cyclosporine bioavailability by ~35%. [2]
Effect: Elevated cyclosporine levels → nephrotoxicity and immunosuppression toxicity. [2]
Action: Contraindicated without therapeutic drug monitoring. Adjust cyclosporine dose or avoid berberine [2].
Statins (particularly simvastatin, atorvastatin) Major
Mechanism: CYP3A4 inhibition increases statin blood levels. [2]
Effect: Increased risk of statin myopathy and rhabdomyolysis. [2]
Action: If combining, use rosuvastatin (not CYP3A4-metabolized) or monitor closely. Lower statin dose may be needed [2].
CYP2D6 substrates (codeine, fluoxetine, tamoxifen) Moderate
Mechanism: Berberine inhibits CYP2D6. [2]
Effect: Altered metabolism of CYP2D6 substrates. Codeine may have reduced analgesic effect (less conversion to morphine). Tamoxifen may have reduced active metabolite. [2]
Action: Be aware of CYP2D6 interaction potential. Clinical significance varies by drug [2].
Supplement synergies
Alpha-Lipoic Acid · 300–600 mg/day ALA
Both improve insulin sensitivity through complementary mechanisms (AMPK + GLUT4). Combined use for metabolic syndrome [2].
Both improve insulin sensitivity through complementary mechanisms (AMPK + GLUT4). Combined use for metabolic syndrome [2].
Chromium · 200–1,000 µg/day chromium picolinate
Both may improve glucose metabolism. Small studies suggest additive benefit [2].
Both may improve glucose metabolism. Small studies suggest additive benefit [2].
7 Regulatory
United States (FDA): Classified as a dietary supplement. No FDA-approved health claims. Not approved as a drug for diabetes or dyslipidemia [1].
European Union (EFSA): Some EU countries restrict or ban berberine-containing supplements (Italy limits to 500 mg/day). No authorized health claims [1].
China (NMPA): Berberine hydrochloride (Huang Lian Su) is an approved OTC drug for bacterial diarrhea [1].
South Korea (MFDS): Available as dietary supplement ingredient with restrictions.
8 US supplement products
37
on-market products containing Berberine (NIH DSLD)
Brands carrying Berberine (29)
Click a brand to see its Berberine products.
9 Frequently paired with
10 Cite this page
Vancouver: Pkhakadze G. Berberine — safety profile [Internet]. Tbilisi: PHIG; 2026 [cited 2026 Sep 01]. Available from: https://supplement.ge/ingredients/berberine/
APA 7th: Pkhakadze, G. (2026). Berberine — Safety profile. Public Health Institute of Georgia. https://supplement.ge/ingredients/berberine/
📋 Editorial information
Author: Prof. G. Pkhakadze, MD, MPH, PhD
Institution: Public Health Institute of Georgia (PHIG)
Affiliation: David Tvildiani Medical University (DTMU)
First published: January 2026
Last reviewed: 2026-05-29
Next review: March 2027
References: 5 cited sources
COI: SupplementIndex receives no funding from supplement manufacturers. All content independently authored by PHIG.
Process: Systematic literature review
📄 License & reuse
Published under Creative Commons Attribution 4.0 International (CC BY 4.0). You may share and adapt for any purpose with attribution.
Pkhakadze G. "Berberine — Safety Profile." SupplementIndex, PHIG, 2026. https://supplement.ge/ingredients/berberine/ CC BY 4.0.
GP
Prof. G. Pkhakadze, MD, MPH, PhD
Professor of Public Health · Head of Department, DTMU
Editor-in-Chief, Georgian Medical Journal (ISSN 3088-4322)
Chair, Public Health Institute of Georgia · UEMS Public Health Section
Educational and public health purposes. CC BY 4.0. Consult your healthcare provider before starting any supplement. Corrections: info@accreditation.ge. Publisher: PHIG